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Abstract 
Background: Pancreatic cancer often goes undiagnosed until late stage disease due in part to suboptimal early 
detection. Our goal was to develop a Syndecan‑1 tagged liposome containing fluorescent dye as an improved con‑
trast agent for detection of pancreatic adenocarcinoma in vivo using multispectral optoacoustic tomography.
Results: The diagnostic capabilities and specificity to pancreatic adenocarcinoma of Syndecan‑1 targeted liposomes 
were evaluated both in vitro and in vivo. Immunocytochemistry showed that liposomes preferentially bound to and 
released their contents into cells expressing high levels of insulin‑like growth factor 1 receptor. We determined that 
the contents of the liposome were released into the cell as noted by the change in propidium iodide fluorescence 
from green to red based upon nucleic acid binding. In an orthotopic mouse model, the liposomes preferentially tar‑
geted the pancreatic tumor with little off‑target binding in the liver and spleen. Peak accumulation of the liposomes 
in the tumor occurred at 8 h post‑injection. Multispectral optoacoustic tomographic imaging was able to provide 
high‑resolution 3D images of the tumor and liposome location. Ex vivo analysis showed that non‑targeted liposomes 
accumulated in the liver, suggesting that specificity of the liposomes for pancreatic adenocarcinoma was due to the 
presence of the Syndecan‑1 ligand.
Conclusions: This study demonstrated that Syndecan‑1 liposomes were able to release cargo into IGF1‑R expressing 
tumor cells. The Syndecan‑1 liposomes demonstrated tumor specificity in orthotopic pancreatic cancer as observed 
using multispectral optoacoustic tomography with reduced kidney and liver uptake. By targeting the liposome with 
Syndecan‑1, this nanovehicle has potential as a targeted theranostic nanoparticle for both drug and contrast agent 
delivery to pancreatic tumors.
© 2015 Yin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pancreatic adenocarcinoma has retained a high mortal-
ity rate due to inadequate early detection methods and 
the relative ineffectiveness of current therapy regimens 
[1–4]. In particular, the underlying biology of pancreatic 
ductal adenocarcinoma can make these tumors particu-
larly resistant to chemotherapy. The dense desmoplas-
tic stroma and poor vascularity of these tumors inhibits 
the accumulation of traditional chemotherapies, and 
prevents therapeutic drug concentrations from being 
realized within the tumor [5]. Nanoparticle drug carriers 
are an effective strategy to overcome these extracellular 
barriers to drug delivery, and can increase the therapeu-
tic load at tumor sites while decreasing systemic toxicity 
[6–8]. Liposomes in particular have multiple desirable 
characteristics, such as the capacity for encapsulating 
large amounts of materials, the ability to protect these 
materials from degradation, and the capability for intra-
cellular delivery through fusion with the plasma mem-
brane [9].
In addition to being drug carriers, liposomes can also 
encapsulate contrast agents for diagnostic imaging, com-
bining diagnostic and therapeutic functions into one sys-
tem. These particles, termed “theranostic nanoparticles”, 
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are a novel approach for detecting, monitoring, and 
treating cancer [10, 11]. The contrast agents loaded into 
theranostic nanoparticles allow nanoparticle accumula-
tion and biodistribution to be tracked using standard 
techniques such as planar fluorescent imaging [12].
However, multi-spectral optoacoustic tomography 
(MSOT) offers several advantages over traditional imag-
ing modalities. MSOT operates via the photoacoustic 
effect, wherein a medium excited by pulsed laser light 
subsequently emits an acoustic wave. Optically active 
molecules, or chromophores, absorb a photon and enter 
an excited state, generating heat upon relaxation. This 
pulse of heat leads to an increase in temperature and 
local pressure, termed thermoelastic expansion. Propaga-
tion of the pressure differential results in the formation of 
an acoustic wave, which can then be recorded with ultra-
sound detectors to create high-resolution 3D images [13, 
14]. Expansion of endogenous and exogenous chromo-
phores occur at specific excitation wavelengths, allow-
ing for selective imaging of compounds of interest. Due 
to the low-scattering characteristic of ultrasonic waves, 
images do not suffer from the light scattering or signal 
attenuation that limits optical and fluorescent imaging. 
Additional advantages include an enhanced spatial reso-
lution of up to 150 µm and accurate 3D imaging of deep 
tissue layers [14–18]. Furthermore, multi-wavelength 
measurements can be used to quantify spatially varying 
concentrations of chromophores within biological tissues 
[13]. MSOT can therefore be a valuable tool in determin-
ing the precise location and relative concentration of 
theranostic nanoparticles in vivo.
Syndecan-1 (Sdc1) has been shown to bind specifically 
to pancreatic adenocarcinoma, making it a promising 
targeting ligand for a theranostic nanoparticle [19, 20]. 
This study examines the feasibility of using Syndecan-1 
tagged liposomes as a theranostic nanoparticle for pan-
creatic adenocarcinoma, using MSOT to evaluate the 




Pancreatic adenocarcinoma cell lines S2VP10 and S2013, 
metastatic subclones of the SUIT-2 line, were obtained 
from Dr. Michael A. Hollingsworth at the University of 
Nebraska. Squamous cell carcinoma cell line SCC-1 was 
obtained from the University of Michigan. Pancreatic 
adenocarcinoma cell line MiaPaCa-2 was obtained from 
ATCC (Manassas, VA, USA). S2VP10, S2013, and SCC-1 
cells were cultured in RPMI 1640 and MiaPaCa-2 cells in 
DMEM medium (Gibco, Grand Island, NY, USA), sup-
plemented with 10  % Fetal Bovine Serum (Atlanta Bio-
logicals, Flowery Branch, GA, USA) and 1 % l-Glutamine 
(Gibco). The cells were cultured at 37  °C and 5  % CO2. 
S2VP10 cells were infected with a retrovirus containing 
the firefly luciferase (Luc) gene (Stratagene, La Jolla, CA, 




Soybean l-α-phosphatidylcholine (95 %) (PC), 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-diole-
oyl-sn-glycero-3-phosphoethanolamine-N-(hexanoylamine) 
(CAP) were purchased from Avanti Polar Lipids (Alabaster, 
AL, USA) (Additional file 1: Figure S1). N-Hydroxysulfosuc-
cinimide sodium salt (NHS), N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) and propidium 
iodide were purchased from Sigma (St. Louis, MO, USA). 
CF-750  N-hydroxysuccinimide ester amine-reactive dye 
was purchased from Biotium (Hayward, CA, USA). Finally, 
Syndecan-1 (Sdc1) was purchased from Prospec (Rehovot, 
Israel).
Synthesis of propidium iodide and CF‑750 encapsulated 
liposomes
Naked liposomes were synthesized by thin film hydration 
method [22]. Soybean PC (0.0067 g), CAP (0.0023 g) and 
DOPE (0.0020 g) were dissolved in chloroform. Then, the 
chloroform was evaporated by heating at 70 °C for 10 min 
in a rotary evaporator to get a thin film of lipids. The thin 
film was hydrated by adding 1  mL PBS (pH 7.4, 0.9  % 
NaCl) and propidium iodide or CF-750 (1 mM, 0.1 mL) 
for 2 h at 70 °C. Then, the liposomes were sonicated for 
2 h at 70 °C. Finally, liposomes were extruded four times 
through a polycarbonate filter (200 nm) at 70 °C.
Conjugation of Syndecan‑1 to dye‑encapsulated liposomes
Syndecan-1 was conjugated to the dye-encapsulated 
naked liposomes by carbodiimide chemistry. Syndecan-1 
(0.74 mM, 20 μl) was mixed with NHS (1 mM, 0.1 mL) 
and EDC (1 mM, 0.1 mL) and incubated for 6 h at room 
temperature at pH 7.5. Then, 1  mL of liposomes was 
added to this solution and mixed for 1 day at room tem-
perature. The excess NHS, EDC, and Sdc1 were removed 
by dialysis, minimum 2000–3000 Da. The stock solution 




The size distribution of the liposomes was analyzed by 
dynamic light scattering (DLS) using a Zetasizer Nano-
ZS (Malvern Instruments Ltd., Malvern, UK). The detec-
tion angle was 173 degrees and the incident beam was 
a He–Ne ion laser (λ =  633  nm). Correlation functions 
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were analyzed by a histogram method and used to deter-
mine the diffusion coefficient (D) of the micelles in the 
sample. Hydrodynamic radius (Rh) was calculated from 
D by using Stokes–Einstein’s equation:
where kB is Boltzmann’s constant, T is absolute tempera-
ture, and η is solvent viscosity [23].
Zeta‑potential measurements
Electrophoretic mobility (μE) of the liposomes was meas-
ured at 25  °C with the Zetasizer Nano-ZS. The zeta-
potential of the samples was calculated from μE using 
following Smoluchowski’s equation:
where ζ is the zeta-potential, ε the permittivity of solvent, 
and η the solvent viscosity [23].
Transmission electron microscopy
10  μL of 1  mM liposomes were dropped on 200 mesh 
copper grids (Electron Microscopy Sciences, Hatfield, 
PA, USA) and dried at room temperature for 5 h. Images 
were collected using the Phillips CM-10 transmission 
electron microscope at 80 kV, equipped with a 15 mega-
byte SIA digital camera.
UV–Vis spectroscopy
The absorption spectrum for the CF-750 encapsulated 
liposomes was analyzed via UV–Visible spectroscopy. 
Absorption at wavelengths every 10 nm between 650 and 
860  nm was measured using the NanoDrop 2000 Spec-
trophotometer (Thermo Scientific, Waltham, MA, USA) 
and accompanying software. Near-infrared (NIR) fluores-
cence signal was confirmed using Li-Cor Odyssey infra-
red scanner (Li-Cor, Lincoln, NE, USA).
Western blot analysis
Whole cell lysates from S2VP10L, MiaPaCa-2, S2013, 
and SCC-1 cells were collected to determine IGF1R 
expression. The cells were plated at a density of 5x105 
cells per well in a 6-well plate 24 h prior to protein har-
vest. Cells were then lysed in a solution containing 1  % 
NP-40, 1  % protease inhibitor, and 1  % phosphatase 
inhibitor (Thermo) in deionized water. The lysates were 
centrifuged at 13,000×g for 10  min. Total protein con-
centration was determined via Bradford assay (Bio-Rad, 
Hercules, CA, USA).
Approximately 50  µg of total protein was dissolved 
in deionized water, loading buffer, and reducing agent 







separated using NuPage 4–12 % Bis–Tris gel and trans-
ferred onto a nitrocellulose membrane by iBlot (Life 
Technologies). The membrane was blocked in block-
ing buffer (Li-Cor) for 30 min and then incubated over-
night at 4  °C with IGF1R antibody (Abcam, Cambridge, 
England) at a concentration of 1  µg/mL and β-Actin 
antibody (Thermo) at a concentration of 1:3000. The 
membrane was then washed 3× with TBS (20 mM Tris–
HCl, 150 mM NaCl in diH2O) for 10 min each, incubated 
with donkey anti-mouse IRDye 680RD and donkey anti-
rabbit IRDye 800CW secondary antibodies (Li-Cor) for 
1 h, washed 3× with TBS for 10 min each, and scanned 
using Li-Cor Odyssey infrared scanner. Dosimetry was 
performed using Li-Cor software.
Immunocytochemistry
S2VP10L and SCC-1 cells were each seeded into 3 wells 
of a chamber slide at a density of 3  ×  105 cells/well. 
Cells were grown overnight in RPMI with 10 % FBS and 
1 % l-Glutamine at 37  °C with 5 % CO2. The cells were 
then serum-starved for 3  h by switching to RPMI with 
1  % BSA (Fisher). Immunocytochemistry buffers were 
prepared as follows: PBS++ (0.5  mM CaCl2 and MgCl2 
in PBS), PBS++++ (97.9  mL PBS++, 2  mL 10  % BSA+ 
90.08  mg dextrose), and citrate buffer (1  mL 20× SCC 
buffer, 19 mL ddH2O). Following starvation, cells of each 
line were treated with 30 μL PBS (control), 30 μL of 1 mM 
naked liposomes, or 30 μL of 1 mM Sdc1 liposomes for 
3 h. Then, the wells were washed 2× with cold PBS++++, 
3× with ice cold citrate buffer, and again 2× with cold 
PBS++++. Cells were fixed with 4  % paraformaldehyde 
(Electron Microscopy Sciences) for 5 min at room tem-
perature and 15 min at 4 °C. Next, the cells were washed 
6× with PBS++ for 10 min each. The slides were mounted 
in ProLong with DAPI (Invitrogen, Waltham, MA, USA) 
and set overnight. Images were taken at 400× magnifica-
tion with a Zeiss Image Photomicroscope 2 (Carl Zeiss, 
Oberkochen, Germany) using DAPI, FITC, and Texas 
Red filters. The exposure times used were 20  ms DAPI, 
200 ms FITC, and 200 ms Texas Red.
Orthotopic pancreatic cancer xenografts
Strict adherence to the University of Louisville Insti-
tutional Animal Care and Use Committee (IACUC)-
approved protocol was maintained throughout the study. 
Five-week old female CB-17 SCID mice (Harlan Labora-
tories, Indianapolis, IN, USA) were acclimated for 1 week 
prior to the study. Mice were anesthetized for all surgical 
procedures with 1.6 % isoflurane and all procedures were 
performed in a sterile hood. Orthotopic cell implantation 
was performed as previously described [15, 21]. A 1-cm 
incision was made in the left upper abdominal quad-
rant and the spleen was located and used to indirectly 
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position the tail of the pancreas, avoiding direct manip-
ulation of the pancreas. The suspension of S2VP10L 
(Luc positive) cells in PBS was stored on ice and drawn 
up with a 28-gauge needle. Five mice were each injected 
with 1.5 × 105 S2VP10L (Luc positive) cells (30 µL) into 
the tail of the pancreas. Sterile cotton-tipped applicators 
were used to cover the injection site for 30 s to prevent 
peritoneal leakage. The organs were repositioned in the 
abdomen and the incision was closed using a single-layer 
closure with 5-0 nylon sutures. The mice recovered on a 
heated pad while receiving clear liquid acetaminophen 
for 24  h with food and water ad  libitum. Confirmation 
of orthotopic implantation was performed using biolu-
minescence optical imaging on the Advanced Molecular 
Imager AMI-1000X (Spectral Imaging Instruments, Tuc-
son, AZ, USA). Mice with detectable leakage from the 
pancreas were removed from the study. Mice received 
intraperitoneal (IP) injection of 2.5  mg luciferin 10  min 
prior to weekly imaging to monitor orthotopic tumor and 
metastatic growth. Region of interest (ROI) analysis was 
used to measure light emitted for orthotopic sites using 
the AMI Image Viewer software. Sutures were removed 
7 days following implantation. At 10 days post-implanta-
tion, mice were IV injected with 200 μL of 100 nM untar-
geted CF-750 or Sdc1-tagged CF-750 liposomes.
In vivo imaging and reconstruction
Multispectral optoacoustic tomographic (MSOT) 
imaging was performed as described by Kimbrough 
et  al. [20]. Mice were anesthetized with 1.6  % isoflu-
rane and prepped for imaging with a combination of 
Nair cream with aloe (Church and Dwight Co., Prince-
ton, NJ, USA) and shaving. The mice were imaged 
using MSOT system InVision TF 256 (iThera Medical, 
Munich, Germany). Serial slice images were taken in 
0.2  mm steps between the diaphragm to the bottom 
of the kidneys (40–55 mm) at wavelengths of 680, 710, 
730, 740, 760, 770, 780, 800, 850, and 900 nm using 25 
averages per wavelength with acquisition time of 10 µs 
per frame [15, 16] in order to minimize the influence of 
animal movement. Images were taken at 4, 8, 16, and 
24 h post injection to track liposome uptake and accu-
mulation. Excitation of CF-750 liposomes was con-
ducted using a tunable parametric oscillator pumped by 
an Nd:YAG laser. The pancreas tumor was identified by 
a live-feed screen preview multispectral signal. Video-
rate acquisition produced an imaging clip compiled 
from single-slice acquisition in less than 1 ms, resulting 
in an image data rate of 10 frames per second. Image 
reconstruction was conducted using backprojection 
at a resolution of 75 µm. Multispectral processing was 
conducted using linear regression (ViewMSOT 3.5). A 
3.5 mm diameter ellipse was used for region-of-interest 
analysis of liposome signal for tumor, liver, and kidney 
as in [15].
Ex vivo imaging of organs
Mice were euthanized 24 h after liposomal injections via 
carbon dioxide inhalation. The pancreas, liver, and spleen 
were harvested and imaged ex vivo to compare accumu-
lation of naked and Sdc1 tagged liposomes from each 
of the five mice imaged using MSOT. The organs were 
imaged using near-infrared (NIR) fluorescence with the 
AMI-1000X at 675 nm excitation and 760 nm emission.
Results and discussion
Western blot
Western blot analysis was performed to evaluate the 
expression of IGF1-R on the three different pancreatic 
adenocarcinoma cell lines (S2VP10L, MiaPaCa-2, and 
S2013). The head and neck squamous cell carcinoma cell 
line SCC-1 served as a negative control. IGF1R plays an 
important role in cell proliferation, tumor metastasis, 
and anti-apoptotic pathways and thus is highly expressed 
in aggressive cancers. High IGF1R expression correlates 
to resistance to chemotherapy and radiation-induced 
apoptosis and is a marker for poor prognosis in pancre-
atic, breast, lung, and prostate cancers [24–29].
As expected, SCC-1 cells expressed much lower lev-
els of IGF1R than pancreatic cancer lines (Fig. 1a). Less 
aggressive MiaPaCa-2 cells also had relatively low IGF1R 
expression. Highly aggressive and metastatic S2VP10L 
and S2013 cells had five- and seven-fold increase of 
IGF1R expression, respectively compared to SCC-1 cells 
(Fig.  1b). S2VP10L cells were chosen as the pancreatic 
cell line to be used for the remainder of the experiments 
due to their predictable behavior in  vivo and relatively 
high levels of IGF1R expression.
Syndecan-1 (Sdc1) is a transmembrane heparin sul-
fate proteoglycan that plays a role in cell proliferation 
and migration. The ectodomain of Sdc1 interacts with 
IGF1R to activate α5β3 integrin, a mechanism not found 
in non-malignant epithelial cells [24, 30, 31]. High IGF1R 
expression in aggressive cancers coupled with the Sdc1–
IGF1R–α5β3 integrin interaction makes targeting IGF1R 
via Sdc1 an attractive option for a theranostic nanoparti-
cle for pancreatic adenocarcinoma.
Characterization of liposomes
Liposomes were synthesized to encapsulate CF-750 dye 
or propidium iodide and tagged with Syndecan-1. Trans-
mission electron microscopy (TEM) of the liposomes 
shows the average size to be 117  nm (Fig.  2c). The size 
of liposomes observed by TEM is smaller than DLS 
(129  nm, Fig.  2a), as TEM yields a number-averaged 
size whereas DLS does a Z-averaged size that takes into 
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account hydration layers. Based on the low polydisper-
sion index, the liposomes are uniform in size (Fig.  2a). 
The liposomes also have a slight positive charge of 0.3 mV 
(Fig. 2b).
The leaky vasculature and inadequate lymphatics 
around solid tumors encourages accumulation of nano-
particles of a particular size (~100  nm), a phenomenon 
termed the enhanced permeability and retention effect 
(EPR) [32]. It is estimated that nanoparticles 60–150 nm 
are small enough to extravasate from the blood into the 
tumor interstitial space through these pores within the 
vasculature [33]. Slightly larger particles such as albumin-
bound chemotherapies with diameters around 130  nm 
also display EPR and are suitable for IV injection [34]. 
Liposomal nanocarriers such as Sdc1-tagged liposomes 
can use passive targeting via EPR to deliver therapeutic 
agents specifically to tumor cells while bypassing normal, 
healthy tissue. Treatment with liposome-encapsulated 
therapeutics have been shown bioavailability of thera-
peutic agents at the tumor site, reduces off-target toxic-
ity, and increases circulation time [35, 36]. Additionally, 
liposomes are permeable in environments with high col-
lagen content, a characteristic of the extracellular matrix 
of pancreatic tumors, making them particularly attractive 
nanoparticles for pancreatic adenocarcinoma [37, 38].
In this study, Syndecan-1 was conjugated to the 
liposomes to act as a targeting ligand, a molecule that 
Fig. 1 Western blot analysis of pancreatic cell lines S2VP10L, Mia‑
PaCa‑2, S2013, and head and neck squamous cell carcinoma cell line 
SCC‑1. a Western blot bands of β‑Actin (42 kDa) and IGF1R (90 kDa). 
b Western blot band intensity dosimetry. The signal intensity of the 
IGF1R band was divided by the signal intensity of the β‑Actin band to 
calculate relative abundance. Relative abundance of IGF1R in nega‑
tive control SCC‑1 cells was approximately 0.06. Pancreatic cell lines 
S2VP10L and S2013 displayed relative abundance of IGF1R of 0.32 
and 0.42, respectively, a five‑ and seven‑fold increase compared to 
the negative control
Fig. 2 a DLS measurements to determine the size of the liposomes. The liposomes are approximately 129 nm in diameter with a polydispersion 
index of 0.05. b Zeta‑potential measurements of the liposomes. Z = 0.3 mV. c Transmission electron microscopy of the liposomes. The average size 
of the liposomes as determined by TEM is approximately 117 nm
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interacts with extracellular or trans-membrane molecules 
on cancer cells [19]. This allows Sdc1-tagged liposomes 
to take advantage of EPR and active targeting of IGF1R 
to enhance specificity for the tumor. Receptor-ligand 
targeting has been shown to improve target cell recogni-
tion within the tumor, leading to increased accumulation 
within cancer cells and increased cellular uptake when 
compared to non-targeted particles [39].
UV–Vis spectroscopy
The absorption spectrum for CF-750 encapsulated Sdc1 
liposomes was analyzed using UV–Vis spectroscopy. The 
peak absorption of the liposomes was 750 nm, the same 
as the original dye (Additional file  2: Figure S2). Thus, 
encapsulating the dye within liposomes does not change 
the optical behavior of the dye.
Immunocytochemistry
Immunocytochemistry slides of S2VP10L and SCC-1 
cells were treated with non-targeted and Sdc1 liposomes 
containing propidium iodide and imaged using Texas 
Red, DAPI, and FITC filters. Fluorescence seen using the 
Texas Red filter indicates propidium iodide (PI) uptake 
by the cell. In IGF1R-positive S2VP10L cells, we found 
greatly increased uptake of PI when treated with Sdc1-
tagged liposomes (Fig. 3c) compared to naked liposomes 
(Fig.  3b). Treatment with non-targeted liposomes does 
not result in the intracellular localization of dye, as the 
green fluorescence indicates extracellular accumula-
tion (Fig. 3e) rather than intracellular uptake. The bright 
yellow areas in Fig.  4f indicate locations where red and 
green light are both present, suggesting PI on both the 
cell surface as well as within the cytoplasm, where it is 
likely bound to mitochondrial DNA or free-floating 
RNA. White areas indicate red, green, and blue co-local-
ization demonstrating the PI binding to nuclear DNA. 
Untreated S2VP10L cells show minimal red autofluores-
cence (Fig. 3a) and no green autofluorescence (Fig. 3d).
Propidium iodide, when bound to nucleic acids, dis-
plays maximum excitation and emission values at 538 
and 617  nm, respectively and fluoresces red using the 
Texas Red filter. However, PI in its free form exhibits 
different optical characteristics: maximum excitation at 
488  nm and emission at 590  nm [40], fluorescing green 
Fig. 3 S2VP10L cells following 3 h treatment at ×400 magnification. All images were taken with the same exposure times. Top row a–c was taken 
with the Texas Red filter. Bottom row d–f was taken with Texas Red, DAPI, and FITC filters. a Untreated control cells show minimal red autofluores‑
cence. b Cells were treated with non‑targeted liposomes display faint red signal, corresponding to minimal dye uptake. c Cells were treated with 
Sdc1 liposomes and a much stronger red fluorescence, indicating uptake of PI and binding of PI to DNA is observed. d Control cells with DAPI. e 
Cells treated with non‑targeted liposomes. Green signal is due to unbound PI, showing dye accumulation outside of the cell. f Cells treated with 
Sdc1 liposomes. Yellow signal occurs due to co‑localization of red and green fluorescence, indicating that dye was located both on the cell surface 
and in the cytoplasm. White signal is colocalization of red, green, and DAPI signal
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using the FITC filter. This allows for distinction between 
excess dye bound on the cell surface versus internalized 
dye bound to nuclear or cytoplasmic nucleic acids.
S2VP10L cells treated with Sdc1 liposomes show dra-
matically increased PI uptake compared to cells treated 
with non-targeted liposomes. The Sdc1–IGF1R interac-
tion may facilitate the liposomes to release their contents 
into the cell. Since this mechanism is specific to IGF1R-
positive cells, chemotherapeutic agents may be loaded 
into Sdc1 liposomes and delivered only to tumor cells. 
Using a nanocarrier of this sort can reduce the incidence 
and intensity of side effects, which results in improved 
patient compliance and prognosis [6–8, 10]. Further-
more, the presence of a contrast agent allows for track-
ing of liposomal movement and accumulation and can be 
used to diagnose pancreatic cancer. Thus, Sdc1-tagged 
liposomes have the potential to fulfill both diagnostic and 
therapeutic functions.
In vivo imaging and reconstruction
Syndecan-1-tagged liposomes were injected 10  days 
post-implantation of the tumor. Liposome accumulation 
in vivo was determined using MSOT imaging at 4, 8, 16, 
24  h post injection. Representative location of organs 
as seen on the MSOT can be viewed in Supplemen-
tal Fig. 3. Liposome accumulation in the tumor peaked 
at 8 h post-injection and declined within 24 h (Fig. 4c). 
The highest region of photoacoustic signal was between 
45 and 46 mm in the mouse, and corresponded with the 
location of the pancreatic tumors (Fig.  4a). Low signal 
Fig. 4 a Serial slice images of liposomal accumulation taken from 43 to 48 mm (abdomen). The highest signal intensity of the liposomes was at 
45–46 mm. Organs are identified: P pancreas tumor, L liver, S spleen, K kidney. b Orthogonal views of the pancreatic tumor and liposomal accu‑
mulation through different anatomical planes. c ROI analysis on liposome signal in various locations over time measured in MSOT a.u. Bar height 
represents the median value and error bars represent the standard deviation throughout the organ. Peak liposomal accumulation occurred at 8 h 
post‑injection. Significantly more liposomes accumulated in the tumor versus off‑target organs (p < 0.05). Representative locations of organs can be 
viewed in Additional file 3: Figure S3
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intensity was observed in the spleen and liver (Fig. 4b), 
indicating significantly more liposomes accumulated in 
the tumor versus in the liver and kidney (p < 0.05). Fur-
thermore, orthogonal views of the tumor demonstrate 
probe accumulation along three spatial dimensions, and 
suggest liposome penetration and accumulation within 
the interior of the pancreatic tumor (Fig.  4b). Error 
bars represent standard deviation throughout the organ 
(Fig. 4c).
The ability to utilize targeting ligands or monoclonal 
antibodies to improve tumor specific uptake of nano-
particles for both imaging and treatment of cancer is one 
of the most important aspects to successfully translate 
nanotechnology to the clinic. This is especially important 
as non-targeted liposomal formulations of chemothera-
peutics, i.e. doxil, have failed to demonstrate significantly 
increased tumor localization in the clinic [41]. The use 
of Syndecan-1 ligand to target the liposomes to the pan-
creatic tumor along with low off-target binding demon-
strates the feasibility of this approach. The ability of these 
particles to contain contrast agents can allow for alterna-
tive methods of imaging pancreatic cancer using current 
imaging technology. Previous studies have shown that 
liposome-encapsulated contrast agents enhance imag-
ing of tumors and inflammatory lesions using CT and 
SPECT by increasing circulation time [42, 43]. Modifying 
the lipid composition of Sdc1-tagged liposomes in this 
way could enhance the use of MRI for pancreatic adeno-
carcinoma by allowing for the imaging of smaller tumors. 
Alternatively, Sdc1-tagged or similar liposomes specific 
to pancreatic cancer can be loaded with a contrast dye 
to better image suspected pancreatic lesions using CT, 
improving an already-established method of imaging 
pancreatic cancer.
Photoacoustic imaging is capable of producing 
high resolution molecular images in  vivo based on 
the absorption of contrast agents. MSOT technology, 
while new, is being established in clinical settings with 
the development of a handheld MSOT system [44]. In 
humans, MSOT has been able to provide high-resolu-
tion and high-contrast imaging of both endogenous 
(such as oxy- and deoxy-hemoglobin, and melanin in 
the monitoring of melanoma) and exogenous (NIR dyes) 
chromophores in the context of cancer [45–47]. Cur-
rently, photoacoustic imaging has been demonstrated at 
depths of up to 5 cm while volumetric real-time photoa-
coustic imaging image has been demonstrated depths of 
up to 1 cm [46].
The use of photoacoustic imaging of pancreatic can-
cer is currently limited by inability to deliver the laser 
pulse to deep organs. However, photoacoustic endos-
copy, currently in the preclinical stage, is emerging as a 
new modality for imaging the GI tract [48]. Endoscopic 
ultrasound is currently used for diagnosis of pancreatic 
cancer via ultrasound-guided needle biopsies of sus-
pected tumors [4]. With further technological advance-
ment, photoacoustic endoscopy can deliver light through 
the lining of the stomach to the pancreas. If used to 
image pancreatic adenocarcinoma-specific chromo-
phores, such as dyes encapsulated within targeted 
liposomes, photoacoustic endoscopy has the potential to 
become a non-invasive method of diagnosing pancreatic 
cancer.
Ex vivo imaging of organs
Ex vivo fluorescent imaging confirms accumulation of 
Sdc1-liposomes within organs (Fig.  5). Mice were euth-
anized 24  h post-liposomal injection. The pancreas, 
liver, and spleen were imaged using NIR fluorescent 
imaging with excitation 675  nm and emission 760  nm. 
Sdc1-tagged liposomes bound preferentially to the pan-
creas tumor with little off-target binding in the liver and 
spleen. While some naked liposomes reached the pancre-
atic tumor, this was likely due to passive targeting from 
EPR and the leakiness of the blood vessels around the 
tumor [32]. Non-targeted liposomes accumulated pri-
marily within the liver.
The dramatic difference in liposome localization 
and specificity was due to the presence of the target-
ing ligand, Syndecan-1. Sdc1 provided a mechanism 
for the liposomes to actively target pancreatic cancer 
by binding to IGF1R, overexpressed on S2VP10L cells 
(Fig.  1). Active targeting enhanced the specificity of 
the liposomes for pancreatic cancer when compared to 
untargeted liposomes, which is in congruence with pre-
vious studies [39].
Conclusion
Syndecan-1 tagged liposomes actively target pancreatic 
adenocarcinoma with minimal off-target binding in vivo. 
Using liposomes that contained contrast agents allowed 
for non-invasive tracking via photoacoustic imaging, 
and MSOT was able to provide high-resolution molecu-
lar images of our Syndecan-1 liposomes in an orthotopic 
pancreatic xenograft mouse model. Ex vivo analysis of 
non-targeted and Syndecan-1 liposomes show that unlike 
naked liposomes, Syndecan-1 liposomes do not primarily 
accumulate in off-target organs such as the liver. In this 
study, the liposomes only contained a fluorescent dye for 
diagnostic imaging; in the future, these liposomes may 
serve as a nanocarrier for chemotherapeutic agents. Our 
in vitro results demonstrate improved intracellular deliv-
ery of liposomal content into tumor cells using targeted 
liposomes. Future studies should explore the ability of 
Syndecan-1 liposomes to preferentially release drugs at 
the tumor site and compare their effectiveness to current 
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treatments for pancreatic cancer. Ultimately these studies 
may lead to the development of a theranostic nanoparti-
cle for clinical use.
Authors’ contributions
WY carried out evaluation of IGF1‑R expression by western blot, construction 
and characterization of liposomes, assisted in the immunocytochemistry, and 
aided in the drafting of the manuscript. CWK and LRM carried out the in vivo 
experiments including orthotopic mouse injection, IV liposome injection, 
in vivo imaging, and drafting of the manuscript. JG G‑G and CTB participated 
in characterization of the liposome and drafting the manuscript. PC aided 
in the characterization and construction of the liposomes. WEG participated 
in the immunocytochemistry experiments and acquisition of images. LRM 
conceived of the study and coordinated the experiments. All authors read and 
approved the final manuscript.
Author details
1 University of Louisville, 505 S Hancock, Louisville, KY 40202, USA. 2 University 
of Alabama Birmingham, ZRB 408, 1720 2nd Avenue South, Birmingham, AL 
35294, USA. 
Additional files
Additional file 1: Figure S1.  Structures of the lipids used for control and 
Sdc1‑tagged liposome synthesis.
Additional file 2: Figure S2. Absorption spectrum for CF‑750 encapsu‑
lated Sdc1 liposomes. The liposomes demonstrated fluorescence activity 
with peak absorbance at 750 nm. Encapsulating the CF‑750 dye within 
the Sdc1 liposomes did not change the optical activity of the dye.
Additional file 3: Figure S3.  Representative locations of organs on 
MSOT at both 46 and 49 mm. Organs are noted PT = Pancreas tumor, S = 
Spleen, L = Liver, BV = Blood vessel, K = Kidney.
Acknowledgements
This work was funded in part by the Rounsavall Foundation the University of 
Louisville School of Medicine and the UAB/UMN SPORE in Pancreatic Cancer: 
Tissue Resources and Molecular Pathology Core 2P50CA101955.
Competing interests
The authors declare that they have no competing interests.
Received: 29 July 2015   Accepted: 19 October 2015
References
 1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 
2004;363(9414):1049–57.
 2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, 
Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen 
HS, Feuer EJ, Cronin KA (eds) SEER cancer statistics review, 1975–2010, 
National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/
csr/1975_2010/, based on November 2012 SEER data submission, posted 
to the SEER web site, April 2013.
 3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, 
Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson 
R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and 
clinical benefit with gemcitabine as first‑line therapy for patients 
with advanced pancreas cancer: a randomized trial. J Clin Oncol. 
1997;15(6):2403–13.
 4. Agarwal B, Abu‑Hamda E, Molke KL, Correa AM, Ho L. Endoscopic 
ultrasound‑guided fine needle aspiration and multidetector spiral 
CT in the diagnosis of pancreatic cancer. Am J Gastroenterol. 
2004;99(5):844–50.
 5. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcom‑
ing drug resistance in pancreatic cancer. Expert Opin Ther Targets. 
2011;15(7):817–28.
Fig. 5 Ex vivo fluorescent imaging of the pancreas, liver, and spleen 24 h post‑injection. Sdc1 liposomes accumulated in the tumor with very little 
off‑target binding in the liver and spleen. Non‑targeted liposomes tend to accumulate in the liver with low signal in the tumor
Page 10 of 11Yin et al. J Nanobiotechnol  (2015) 13:90 
 6. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders 
M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, 
Mukherjeel P, Mukhopadhyay D. Targeted delivery of gemcitabine to pan‑
creatic adenocarcinoma using cetuximab as a targeting agent. Cancer 
Res. 2008;68(6):1970–8.
 7. He Y, Zhang L, Zhu D, Song C. Design of multifunctional magnetic iron 
oxide nanoparticles/mitoxantrone‑loaded liposomes for both magnetic 
resonance imaging and targeted cancer therapy. Int J Nanomedicine. 
2014;22(9):4055–66.
 8. Schleich N, Po C, Jacobs D, Ucakar B, Gallez B, Danhier F, Préat V. Compari‑
son of active, passive and magnetic targeting to tumors of multifunc‑
tional paclitaxel/SPIO‑loaded nanoparticles for tumor imaging and 
therapy. J Control Release. 2014;28(194):82–91.
 9. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate 
receptor‑mediated endocytosis. J Biol Chem. 1994;269(5):3198–204.
 10. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in 
nanomedicine: therapeutic, diagnostic, and theranostic applications. Curr 
Opin Biotechnol. 2013;24(6):1159–66.
 11. Fang C, Zhang M. Nanoparticle‑based theragnosticss: integrating diag‑
nostic and therapeutic potentials in nanomedicine. J Control Release. 
2010;146(1):2–5.
 12. Ryu JH, Koo H, Sun IC, Yuk SH, Choi K, Kim K, Kwon IC, Fang C, Miqin Z. 
Tumor‑targeting multi‑functional nanoparticles for theragnosis: new 
paradigm for cancer therapy. Adv Drug Deliv Rev. 2012;64(13):1447–58.
 13. Cox B, Laufer JG, Arridge SR, Beard PC. Quantitative spectroscopic 
photoacoustic imaging: a review. Biomed Opt. 2012;17(6):061202. 
doi:10.1117/1.JBO.17.6.061202.
 14. Razansky D, Deliolanis NC, Vinegoni C, Ntziachristos V. Deep tissue opti‑
cal and optoacoustic molecular imaging technologies for pre‑clinical 
research and drug discovery. Curr Pharm Biotechnol. 2012;13(4):504–22.
 15. Kimbrough CW, Khanal A, Zeiderman M, Khanal BR, Burton NC, McMas‑
ters KM, Vickers SM, Grizzle WE, McNally LR. Targeting acidity in pancreatic 
adenocarcinoma: multispectral optoacoustic tomography detects ph‑low 
insertion peptide probes in vivo. Clin Cancer Res. 2015;21(20):4576–85.
 16. Buehler A, Herzog E, Ale A, Smith BD, Ntziachristos V, Razansky D. High 
resolution tumor targeting in living mice by means of multispectral 
optoacoustic tomography. EJNMMI Res. 2012;2:14.
 17. Lutzweiler C, Razansky D. Optoacoustic imaging and tomography: recon‑
struction approaches and outstanding challenges in image performance 
and quantification. Sensors. 2013;13(6):7345–84.
 18. Ntziachristos V, Razansky D. Molecular imaging by means of multispectral 
optoacoustic tomography (MSOT). Chem Rev. 2010;110(5):2783–94.
 19. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to 
tumors: principles, pitfalls and (pre‑) clinical progress. J Control Release. 
2012;161(2):175–87.
 20. Kimbrough CW, Hudson S, Khanal A, Egger ME, McNally LR. Orthotopic 
pancreatic tumors detected by optoacoustic tomography using Synde‑
can‑1. J Surg Res. 2015;193(1):246–54.
 21. McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC. KISS1 
over‑expression suppresses metastasis of pancreatic adenocarcinoma in 
a xenograft mouse model. Clin Exp Metastasis. 2010;27(8):591–600.
 22. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and 
applications. Int J Pharm Sci Res. 2012;3(2):14–20.
 23. Khanal A, Ullum C, Kimbrough CW, Garbett NC, Burlison JA, McNally MW, 
Chuong P, El‑Baz AS, Jasinski JB, McNally LR. Tumor targeted mesoporous 
silica‑coated gold nanorods facilitate detection of pancreatic tumors 
using Multispectral optoacoustic tomography. Nano Res. 2015. doi:10. 
1007/ s12274‑015‑0886‑8.
 24. Ouban A, Muracab P, Yeatman T, Coppola D. Expression and distribu‑
tion of insulin‑like growth factor‑1 receptor in human carcinomas. Hum 
Pathol. 2003;34(8):803–8.
 25. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan 
L, Burgaud JL, Carter D, Baserga R, Glazer PM. Insulin‑like growth factor‑I 
receptor overexpression mediates cellular radioresistance and local 
breast cancer recurrence after lumpectomy and radiation. Cancer Res. 
1997;57(15):3079–83.
 26. Hirakawa T, Yashiro M, Murata A, Hirata K, Kimural K, Amano R, Yamadal 
N, Nakata B, Hirakawa K. IGF‑1 receptor and IGF binding protein‑3 might 
predict prognosis of patients with resectable pancreatic cancer. BMC 
Cancer. 2013;13:392.
 27. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, Solo‑
mides C, Peiper SC, Witkiewicz AK. Epidermal growth factor receptor and 
insulin like growth factor 1 receptor expression predict poor survival in 
pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484–93.
 28. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, 
Williams S, Wakeling AE, Nicholson RI. Insulin‑like growth factor‑I receptor 
signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human 
breast and prostate cancer cells. Endocr Relat Cancer. 2004;11(4):793–814.
 29. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF, Macaulay 
VM. Expression of the type 1 insulin‑like growth factor receptor is up‑reg‑
ulated in primary prostate cancer and commonly persists in metastatic 
disease. Cancer Res. 2002;62(10):2942–50.
 30. Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan‑1 ectodomain 
regulates alphavbeta3 integrin activity in human mammary carcinoma 
cells. J Cell Biol. 2004;167:171–81.
 31. Beauvais DM, Rapraeger AC. Syndecan‑1 couples the insulin‑like 
growth factor‑1 receptor to inside‑out integrin activation. J Cell Sci. 
2010;123(21):3796–807.
 32. Maeda H, Greish K, Fang J. The EPR effect and polymeric drugs: a para‑
digm shift for cancer chemotherapy in the 21st century. Satchi‑Fainaro 
R, Duncan R, editors. Polymer therapeutics II, vol 193. Berlin, Heidelberg: 
Springer; 2006. p. 103–21.
 33. Prabhakar U, Maeda H, Jain RK, Sevick‑Muraca EM, Zamboni W, 
Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DV. Challenges 
and key considerations of the enhanced permeability and reten‑
tion effect for nanomedicine drug delivery in oncology. Cancer Res. 
2013;73(8):2412–7.
 34. Kim DH, Moon C, Oh SS, Park S, Jeong JW, Kim S, Lee HG, Kwon HJ, Kim 
KD. Liposome‑encapsulated CpG enhances antitumor activity accompa‑
nying the changing of lymphocyte populations in tumor via intratumoral 
administration. Nucleic Acid Ther. 2015;25(2):95–102.
 35. Andey TA, Sudhakar G, Marepally SK, Patel AR, Banerjee R, Sachdeva MS. 
Lipid nanocarriers of a lipid‑conjugated estrogenic derivative inhibit 
tumor growth and enhance cisplatin activity against triple‑negative 
breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm. 
2015;12(4):1105–20.
 36. Kroon J, Buijs JT, van der Horst G, Cheung H, van der Mark M, van Bloois L, 
Rizzo LY, Lammers T, Pelger RC, Storm G, van der Pluijm G, Metselaar JM. 
Liposomal delivery of dexamethasone attenuates prostate cancer bone 
metastatic tumor growth in vivo. Prostate. 2015;75(8):815–24.
 37. Yokoi K, Kojic M, Milosevic M, Tanei T, Ferrari M, Ziemys A. Capillary‑wall 
collagen as a biophysical marker of nanotherapeutic permeability into 
the tumor microenvironment. Cancer Res. 2014;74(16):4239–46.
 38. Hidenori M, Tatsuya M, Kunihiro T, Hiromu S, Hidenori M, Seiki T. Tumor‑
stroma interaction of human pancreatic cancer: acquired resistance to 
anticancer drugs and proliferation regulation is dependent on extracel‑
lular matrix proteins. Pancreas. 2004;28(1):38–44.
 39. Watanabe K, Kaneko M, Maitani Y. Functional coating of liposomes using 
a folate‑ polymer conjugate to target folate receptors. Int J Nanomedi‑
cine. 2012;7:3679–88.
 40. Krishan A, Ganapathi RN, Israel M. Effect of adriamycin and analogs on 
the nuclear fluorescence of propidium iodide‑stained cells. Cancer Res. 
1978;38(11 Pt 1):3656–62.
 41. Syrigos KN, Michalaki B, Alevyzaki F, Machairas A, Mandrekas D, Kindilidis 
K, Karatzas G. A phase‑II study of liposomal doxorubicin and doc‑
etaxel in patients with advanced pancreatic cancer. Anticancer Res. 
2002;22(6B):3583–8.
 42. Zheng J, Allen C, Serra S, Vines D, Charron M, Jaffray DA. Liposome 
contrast agent for CT‑based detection and localization of neoplastic and 
inflammatory lesions in rabbits: validation with FDG‑PET and histology. 
Contrast Media Mol Imaging. 2010;5(3):147–54.
 43. Chen MH, Chang CH, Chang YJ, Chen LC, Yu CY, Wu YH, Lee WC, Yeh CH, 
Lin FH, Lee TW, Yang CS, Ting G. MicroSPECT/CT imaging and pharma‑
cokinetics of 188Re‑(DXR)‑liposome in human colorectal adenocarci‑
noma‑bearing mice. Anticancer Res. 2010;30(1):65–72.
 44. Buehler A, Kacprowicz M, Taruttis A, Ntziachristos V. Real‑time handheld 
multispectral optoacoustic imaging. Opt Lett. 2013;38(9):1404–6.
 45. Mallidi S, Luke GP, Emelianov S. Photoacoustic imaging in cancer 
detection, diagnosis, and treatment guidance. Trends Biotechnol. 
2011;29(5):213–21.
Page 11 of 11Yin et al. J Nanobiotechnol  (2015) 13:90 
 46. Deán‑Ben XL, Razansky D. Functional optoacoustic human angiography 
with handheld video rate three dimensional scanner. Photoacoustics. 
2013;1(3–4):68–73.
 47. Heijblom M, Piras D, Xia W, van Hespen JC, Klaase JM, van den Engh 
FM, van Leeuwen TG, Steenbergen W, Manohar S. Visualizing breast 
cancer using the Twente photoacoustic mammoscope: what do 
we learn from twelve new patient measurements? Opt Express. 
2012;20(11):11582–97.
 48. Yoon TJ, Cho YS. Recent advances in photoacoustic endoscopy. World J 
Gastrointest Endosc. 2013;5(11):534–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
